Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.

Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F; EMPEROR-Reduced Trial Committees and Investigators.

Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.

PMID:
31584231
2.

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators.

Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16.

PMID:
31523904
3.

Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.

Nishimura R, Tanaka Y, Koiwai K, Ishida K, Salsali A, Kaspers S, Kohler S, Lund SS.

Adv Ther. 2019 Oct;36(10):2769-2782. doi: 10.1007/s12325-019-01045-x. Epub 2019 Aug 23.

PMID:
31444706
4.

Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.

Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, Brun M, Ustyugova A, Jamal W, Salsali A, Lindenfeld J, Anker SD; EMPERIAL Investigators and National Coordinators.

Eur J Heart Fail. 2019 Jul;21(7):932-942. doi: 10.1002/ejhf.1486. Epub 2019 Jun 19.

5.

Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.

Ferdinand KC, Izzo JL, Lee J, Meng L, George J, Salsali A, Seman L.

Circulation. 2019 Apr 30;139(18):2098-2109. doi: 10.1161/CIRCULATIONAHA.118.036568.

PMID:
30786754
6.

Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.

Ridderstråle M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A; EMPA-REG H2H-SU trial investigators.

Diabetes Obes Metab. 2018 Dec;20(12):2768-2777. doi: 10.1111/dom.13457. Epub 2018 Aug 7.

PMID:
29961998
7.

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.

Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ.

Diabetes Care. 2018 Aug;41(8):1809-1816. doi: 10.2337/dc17-1525. Epub 2018 Jun 15.

PMID:
29907581
8.

Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.

Ferdinand KC, Seman L, Salsali A.

Curr Med Res Opin. 2018 Feb;34(2):361-367. doi: 10.1080/03007995.2017.1405800. Epub 2017 Nov 29.

PMID:
29139301
9.

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program.

Eur J Heart Fail. 2017 Nov;19(11):1390-1400. doi: 10.1002/ejhf.933. Epub 2017 Aug 24. Review.

10.

Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.

Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M.

Circ Heart Fail. 2017 Apr;10(4). pii: e003800. doi: 10.1161/CIRCHEARTFAILURE.116.003800.

11.

Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.

Zimdahl H, Haupt A, Brendel M, Bour L, Machicao F, Salsali A, Broedl UC, Woerle HJ, Häring HU, Staiger H.

Pharmacogenet Genomics. 2017 Apr;27(4):135-142. doi: 10.1097/FPC.0000000000000268.

PMID:
28134748
12.

Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction.

Butler J, Hamo CE, Udelson JE, Pitt B, Yancy C, Shah SJ, Desvigne-Nickens P, Bernstein HS, Clark RL, Depre C, Dinh W, Hamer A, Kay-Mugford P, Kramer F, Lefkowitz M, Lewis K, Maya J, Maybaum S, Patel MJ, Pollack PS, Roessig L, Rotman S, Salsali A, Sims JJ, Senni M, Rosano G, Dunnmon P, Stockbridge N, Anker SD, Zile MR, Gheorghiade M.

Circ Heart Fail. 2016 Nov;9(11). pii: e003358.

PMID:
27756791
13.

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.

Salsali A, Kim G, Woerle HJ, Broedl UC, Hantel S.

Diabetes Obes Metab. 2016 Oct;18(10):1034-40. doi: 10.1111/dom.12734. Epub 2016 Aug 24.

14.

Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.

Yoon KH, Nishimura R, Lee J, Crowe S, Salsali A, Hach T, Woerle HJ.

Diabetes Obes Metab. 2016 Oct;18(10):1045-9. doi: 10.1111/dom.12699. Epub 2016 Jul 13.

PMID:
27265507
15.

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.

Kohler S, Salsali A, Hantel S, Kaspers S, Woerle HJ, Kim G, Broedl UC.

Clin Ther. 2016 Jun;38(6):1299-1313. doi: 10.1016/j.clinthera.2016.03.031. Epub 2016 Apr 13.

16.

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators.

Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26.

17.

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.

Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ MONO investigators.

Cardiovasc Diabetol. 2015 Dec 23;14:154. doi: 10.1186/s12933-015-0314-0.

18.

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.

Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ METSU investigators.

Diabetes Res Clin Pract. 2015 Oct;110(1):82-90. doi: 10.1016/j.diabres.2015.05.044. Epub 2015 May 29.

PMID:
26324220
19.

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.

Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ PIO investigators.

Clin Ther. 2015 Aug;37(8):1773-88.e1. doi: 10.1016/j.clinthera.2015.05.511. Epub 2015 Jun 29.

PMID:
26138864
20.

Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.

Zhao X, Cui Y, Zhao S, Lang B, Broedl UC, Salsali A, Pinnetti S, Macha S.

Clin Ther. 2015 Jul 1;37(7):1493-502. doi: 10.1016/j.clinthera.2015.05.001. Epub 2015 Jun 19.

PMID:
26101175
21.

Empagliflozin as add-on to metformin in people with Type 2 diabetes.

Merker L, Häring HU, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND MET investigators.

Diabet Med. 2015 Dec;32(12):1555-67. doi: 10.1111/dme.12814. Epub 2015 Jul 14.

PMID:
26031566
22.

Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.

Araki E, Tanizawa Y, Tanaka Y, Taniguchi A, Koiwai K, Kim G, Salsali A, Woerle HJ, Broedl UC.

Diabetes Obes Metab. 2015 Jul;17(7):665-74. doi: 10.1111/dom.12464. Epub 2015 Apr 15.

PMID:
25772548
23.

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.

Nishimura R, Tanaka Y, Koiwai K, Inoue K, Hach T, Salsali A, Lund SS, Broedl UC.

Cardiovasc Diabetol. 2015 Jan 30;14:11. doi: 10.1186/s12933-014-0169-9.

24.

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators.

Diabetes Care. 2015 Mar;38(3):420-8. doi: 10.2337/dc14-1096. Epub 2014 Sep 30.

PMID:
25271206
25.

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.

Sarashina A, Ueki K, Sasaki T, Tanaka Y, Koiwai K, Sakamoto W, Woerle HJ, Salsali A, Broedl UC, Macha S.

Clin Ther. 2014 Nov 1;36(11):1606-15. doi: 10.1016/j.clinthera.2014.08.001. Epub 2014 Sep 5.

PMID:
25199997
26.

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.

Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC; EMPA-REG MDI Trial Investigators.

Diabetes Care. 2014 Jul;37(7):1815-23. doi: 10.2337/dc13-3055. Epub 2014 Jun 14.

PMID:
24929430
27.

Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.

Macha S, Koenen R, Sennewald R, Schöne K, Hummel N, Riedmaier S, Woerle HJ, Salsali A, Broedl UC.

Clin Ther. 2014 Feb 1;36(2):280-90.e1. doi: 10.1016/j.clinthera.2014.01.003. Epub 2014 Feb 1.

PMID:
24491572
28.

Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.

Macha S, Jungnik A, Hohl K, Hobson D, Salsali A, Woerle HJ.

Int J Clin Pharmacol Ther. 2013 Nov;51(11):873-9.

PMID:
24152604
29.

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

Rosenstock J, Vico M, Wei L, Salsali A, List JF.

Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23.

30.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF.

Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612. Epub 2010 Jun 21.

31.

Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?

Salsali A, Pratley RE.

Nat Clin Pract Endocrinol Metab. 2007 Jun;3(6):450-1. Epub 2007 Apr 24. No abstract available.

PMID:
17457306
32.

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.

PMID:
17407649
33.

A review of types 1 and 2 diabetes mellitus and their treatment with insulin.

Salsali A, Nathan M.

Am J Ther. 2006 Jul-Aug;13(4):349-61. Review.

PMID:
16858171
34.

Pituitary tumor diagnosis and treatment.

Penar PL, Nathan DJ, Nathan MH, Salsali A.

Curr Neurol Neurosci Rep. 2002 May;2(3):236-45. Review.

PMID:
11937002

Supplemental Content

Loading ...
Support Center